Infigratinib

Drug Profile

Infigratinib

Alternative Names: BGJ-398; NVP-BGJ398

Latest Information Update: 14 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Developer Array BioPharma; Novartis; Novartis Oncology
  • Class Aniline compounds; Antineoplastics; Methylurea compounds; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Haematological malignancies
  • Discontinued Bladder cancer; Glioblastoma; Malignant melanoma; Solid tumours

Most Recent Events

  • 02 Jun 2017 Efficacy and adverse events data from a phase I trial in Solid tumours presented at the 53rd Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 01 Apr 2017 Pharmacodynamics and efficacy data from a phase II trial in Cholangiocarcinoma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 27 Jan 2017 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in France, Canada, Belgium, Singapore, Spain, USA, Australia, Germany, Netherlands, Switzerland, South Korea, Italy (PO) (Novartis 20-F filed in 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top